701 Gateway Blvd Ste 210
South San Francisco, CA, 94080 United States
OXiGENE starves cancer to death. The company's drug candidate, Zybrestat, works by disrupting the functioning of blood vessels that deliver oxygen to tumors. Zybrestat is being investigated as a treatment for patients with ovarian cancer and other forms of cancer. OXiGENE is also working on a second-generation version of its oxygen-starving technology. OXiGene's strategy is to identify and license compounds from academic research centers and then shepherd the compounds through clinical trials. However, it has limited its in-house drug development operations, instead sponsoring research at academic and other research institutions or using contract research organizations.